Explore › Finding
Finding adverse
Retreatment with pegIFN-α-2a and ribavirin was associated with significant cytopenias, dose reductions, and discontinuations, including 8% severe adverse events requiring discontinuation within the first 24 weeks.
Effect size24% treatment discontinuation (23/96)
Follow-up24 weeks
ComparatorNo comparator (single-arm safety assessment)
Effect summaryadverse; 24% treatment discontinuation (23/96)
Adverse eventsanemia <10 g/dL 14%, severe anemia <8.5 3%, neutrophil count <750/mm3 77%, neutrophil count <500/mm3 50%, platelet count <50,000 cells/mm3 5%, RBV dose reduction 19%, PegIFN-α-2a dose reduction 26%, 8% severe AEs requiring discontinuation

Connected entities

Interventions
Pegylated interferon-α-2a and ribavirin
Conditions
Chronic hepatitis C
Outcomes
Treatment-related adverse events

Source

PMC2994950
Insulin Resistance Predicts Retreatment Failure in an Efficacy Study of Peginterferon-α-2a and Ribavirin in HIV/HCV Co-infected Patients
Read on PMC → · View in graph →